UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000018818 |
|---|---|
| Receipt number | R000021766 |
| Scientific Title | Trail against hyperlipidemia Patients with high risks to Investigate the effect ON small dense ldl & idl by using middlE dosE rosuvastatin, atrovastatin, psSk-9 inhibitor(relationship of blood ANGPTL, Sortilin, miRNA and so on level) (PIONEERs in Saitama Study 3) |
| Date of disclosure of the study information | 2015/09/14 |
| Last modified on | 2023/05/30 13:53:32 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2015/08/26 21:50:38 | ||
| 2 | Update | 2015/08/28 20:29:30 | Narrative objectives1 Narrative objectives1 |
|
| 3 | Update | 2015/08/28 20:35:29 | Narrative objectives1 |
|
| 4 | Update | 2015/09/14 21:43:18 | Public title Public title |
|
| 5 | Update | 2015/09/14 21:52:08 | Condition Primary outcomes Primary outcomes |
|
| 6 | Update | 2015/09/14 22:13:10 | Basic design Control No. of arms Interventions/Control_1 Interventions/Control_1 Interventions/Control_2 Interventions/Control_2 |
|
| 7 | Update | 2016/03/26 14:52:50 | Recruitment status |
|
| 8 | Update | 2016/07/29 18:54:04 | Name of primary person or sponsor Organization |
|
| 9 | Update | 2016/07/29 19:04:52 | Public title Public title |
|
| 10 | Update | 2016/07/29 19:11:29 | Narrative objectives1 Narrative objectives1 Primary outcomes Primary outcomes |
|
| 11 | Update | 2016/07/29 19:12:36 | Public title |
|
| 12 | Update | 2016/07/29 19:15:48 | Anticipated trial start date Last follow-up date |
|
| 13 | Update | 2016/07/29 19:27:51 | No. of arms Interventions/Control_3 Interventions/Control_3 Target sample size |
|
| 14 | Update | 2016/07/29 19:39:48 | Public title |
|
| 15 | Update | 2016/07/29 19:45:04 | Public title |
|
| 16 | Update | 2017/09/25 18:48:15 | Interventions/Control_3 Interventions/Control_3 Key exclusion criteria Key exclusion criteria Target sample size |
|
| 17 | Update | 2017/09/25 19:27:00 | Narrative objectives1 Narrative objectives1 Key secondary outcomes Key secondary outcomes |
|
| 18 | Update | 2018/02/27 15:24:51 | Target sample size |
|
| 19 | Update | 2018/02/27 15:25:56 | Publication of results |
|
| 20 | Update | 2018/08/28 11:56:35 | Narrative objectives1 Narrative objectives1 Primary outcomes Primary outcomes Key secondary outcomes Key secondary outcomes |
|
| 21 | Update | 2018/08/28 12:05:40 | Public title Public title |
|
| 22 | Update | 2018/08/28 12:11:29 | Anticipated trial start date Last follow-up date Results Results |
|
| 23 | Update | 2018/08/28 13:48:49 | Narrative objectives1 Narrative objectives1 Key secondary outcomes Key secondary outcomes |
|
| 24 | Update | 2018/08/28 13:59:01 | Key inclusion criteria Key inclusion criteria |
|
| 25 | Update | 2018/08/28 14:02:12 | No. of arms Interventions/Control_4 Interventions/Control_4 |
|
| 26 | Update | 2018/08/28 14:06:51 | Public title |
|
| 27 | Update | 2018/08/28 14:09:12 | Public title |
|
| 28 | Update | 2018/09/07 18:14:30 | Public title Public title Acronym Acronym |
|
| 29 | Update | 2023/05/30 13:52:47 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Zip code Organization2 Address2 Tel2 Email2 Organization3 Address3 Tel3 Email3 Organization Organization Address Address Tel |
|
| 30 | Update | 2023/05/30 13:53:32 | Date of IRB |
